Bellemin-Baurreau J, Poizot A, Hicks P E, Rochette L, Armstrong J M
Department of Pharmacology, Recherche Syntex France, Leuville-sur-Orge.
Eur J Pharmacol. 1994 Apr 21;256(2):115-24. doi: 10.1016/0014-2999(94)90235-6.
The effects of glibenclamide and BRL-38227 were studied in isolated rabbit hearts subjected to ischemia and programmed electrical stimulation. Coronary artery occlusion over 24 min decreased the ventricular effective refractory period in the ischemic zone. BRL-38227 (0.1 microM) showed significant coronary vasodilator effects, but failed to modify the ventricular effective refractory period under these conditions. A higher concentration (5 microM) of BRL-38227 potentiated the ischemia induced ventricular effective refractory period shortening effects. Glibenclamide (0.1 and 1 microM) delayed the onset of the ischemia-induced ventricular effective refractory period shortening. Glibenclamide (1 microM) inhibited the potentiated ventricular effective refractory period shortening effects of BRL-38227 (5 microM) during ischemia, but failed to antagonise the coronary vasodilator effects of BRL-38227 (5 microM). A higher incidence of ventricular fibrillation was inducible when an extra beat was applied in the ischemic zone through programmed electrical stimulation. The incidence of programmed electrical stimulation induced ventricular fibrillation was increased by BRL-38227 (5 microM) and antagonised by glibenclamide (1 microM). The results suggest that high concentrations of KATP-activators can accentuate ischemia-induced decreases in refractory period and increase the susceptibility of hearts to ventricular fibrillation when an extra beat is applied to the ischemic myocardium. These effects did not occur at lower coronary vasodilating concentrations of BRL-38227.
在离体兔心脏上研究了格列本脲和BRL-38227对缺血及程序性电刺激的影响。冠状动脉闭塞24分钟以上可使缺血区心室有效不应期缩短。BRL-38227(0.1微摩尔)显示出显著的冠状动脉舒张作用,但在此条件下未能改变心室有效不应期。较高浓度(5微摩尔)的BRL-38227增强了缺血诱导的心室有效不应期缩短作用。格列本脲(0.1和1微摩尔)延迟了缺血诱导的心室有效不应期缩短的起始时间。格列本脲(1微摩尔)在缺血期间抑制了BRL-38227(5微摩尔)增强的心室有效不应期缩短作用,但未能拮抗BRL-38227(5微摩尔)的冠状动脉舒张作用。当通过程序性电刺激在缺血区施加额外刺激时,更容易诱发心室颤动。BRL-38227(5微摩尔)增加了程序性电刺激诱发心室颤动的发生率,而格列本脲(1微摩尔)则拮抗了这一作用。结果表明,高浓度的KATP激活剂可加重缺血诱导的不应期缩短,并增加当对缺血心肌施加额外刺激时心脏对心室颤动的易感性。在BRL-38227较低的冠状动脉舒张浓度下未出现这些效应。